Article
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Neuro-oncology - 1 Sept 2013
Zhang Chunzhi, Moore Lynette M, Li Xia, Yung W K Alfred, Zhang Wei
Abstract excerpt
Isocitrate dehydrogenase (IDH) enzymes have recently become a focal point for research aimed at understanding the biology of glioma. IDH1 and IDH2 are mutated in 50%-80% of astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas but are seldom mutated in primary glioblastomas. Gliomas with IDH1/2 mutations always harbor other molecular aberrations, such as TP53 mutation or 1p/19q loss....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.